The approval is supported by findings from the phase 3 LITESPARK-005 trial.
The FDA has approved belzutifan (Welireg) for the treatment of patients with advanced renal cell carcinoma (RCC) who have progressed following treatment with a PD-1 or PD-L1 inhibitor and a VEGF-TKI, announced Merck, the developer of the drug, in a news release.1
This approval of belzutifan introduces a meaningful new treatment option for certain patients, as belzutifan reduced the risk of disease progression or death compared [with] everolimus,” said Toni K. Choueiri, MD.
The approval is supported by findings from the phase 3 LITESPARK-005 trial (NCT04195750), in which belzutifan demonstrated superior progression-free survival (PFS) vs everolimus in patients with advanced RCC whose tumors had progressed following treatment. Specifically, the risk of disease progression or death was reduced by 25% with belzutifan (HR, 0.75; 95% CI, 0.63-0.90; P = .0008). The objective response rate (ORR) among patients who received belzutifan was 22% (95% CI, 18-27), compared with 4% (95% CI, 2-6) among patients who received everolimus.
“Despite recent progress in the treatment of advanced RCC, there is yet to be an option specifically approved for patients whose disease progresses following a PD-1 or PD-L1 inhibitor and a TKI therapy,” Toni K. Choueiri, MD, LITESPARK-005 study chair, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and a Jerome and Nancy Kohlberg professor of medicine at Harvard Medical School, stated in the news release.1 “This approval of belzutifan introduces a meaningful new treatment option for certain patients, as belzutifan reduced the risk of disease progression or death compared [with] everolimus.”
In total, the randomized, open-label, active-controlled phase 3 LITESPARK-005 trial enrolled 746 patients with unresectable, locally advanced, or metastatic RCC. Participants were randomly assigned 1:1 to receive 120 mg of belzutifan orally once daily (n = 374) or 10 mg of everolimus orally once daily (n = 372). The median duration of exposure among patients who received belzutifan was 7.6 months (range, 0.1–28.5).
The primary end point was PFS, as determined by blinded independent central review based on RECISTv1.1, and overall survival. Key secondary end points included ORR, duration of response, and safety/tolerability.2
Median PFS among patients in the belzutifan cohort was 5.6 months (95% CI, 3.9-7.0) versus 5.6 months (95% CI, 4.8-5.8) for everolimus. In total, 82 patients (22%) in the belzutifan arm demonstrated a response, with a complete response (CR) rate of 3% (n = 10) and a partial response (PR) rate of 19% (n = 72). Among the 82 patients with a response in the belzutifan arm, 25 patients (30%) achieved a duration of response of at least 12 months. ORR among patients in the everolimus arm was 4%, with no patients achieving a CR and a PR rate of 4% (n = 13). Overall survival results were immature.
Regarding safety, 38% of patients who received belzutifan experienced a serious adverse event (AE), including hypoxia (7%), anemia (5%), pneumonia (3.5%), hemorrhage (3%) and pleural effusion (2.2%). Fatal AEs occurred in 3.2% of patients, and 6% of patients discontinued treatment due to AEs. Dose interruptions due to AEs occurred in 39% of patients, and dose reductions due to AEs occurred in 13% of patients.
There is a boxed warning on the belzutifan label stating that exposure to belzutifan during pregnancy can cause embryo-fetal harm.
Marjorie Green, MD, senior vice president and head of late-stage oncology of global clinical development at Merck Research Laboratories, concluded in the news release, “In 2021, Welireg became the first HIF-2α inhibitor therapy approved in the U.S. for the treatment of adult patients with certain [von Hippel-Lindau] disease-associated tumors and is now approved for eligible patients with advanced RCC. This approval of Welireg marks the first new therapeutic class available for eligible patients with advanced RCC in nearly a decade and was based on the statistically significant progression-free survival benefit observed in patients following treatment with a PD-1 or PD-L1 inhibitor and a VEGF-TKI when compared to everolimus.”1
References
1. FDA approves Merck’s WELIREG (belzutifan) for the treatment of patients with advanced renal cell carcinoma (RCC) following a PD-1 or PD-L1 inhibitor and a VEGF-TKI. News release. Merck. December 14, 2023. Accessed December 15, 2023. https://www.businesswire.com/news/home/20231214762284/en/FDA-Approves-Merck%E2%80%99s-WELIREG%C2%AE-belzutifan-for-the-Treatment-of-Patients-With-Advanced-Renal-Cell-Carcinoma-RCC-Following-a-PD-1-or-PD-L1-Inhibitor-and-a-VEGF-TKI
2. A study of belzutifan (MK-6482) versus everolimus in participants with advanced renal cell carcinoma (MK-6482-005). ClinicalTrials.gov. Last updated August 1, 2022. Accessed December 15, 2023. https://clinicaltrials.gov/study/NCT04195750
Adding nivolumab to low-dose tivozanib does not improve PFS in renal cell carcinoma
July 19th 2024"While the addition of an ICI to low dose FOTIVDA did not improve PFS outcomes after prior ICI, we consider the control arm data an important, evidence-based and clinically meaningful contribution to the oncology community treating relapsed or refractory advanced RCC following front-line ICI combinations," says Michael P. Bailey.
Live bacterial supplementation may improve TKI-based treatment efficacy in kidney cancer
June 30th 2024CBM588 could be exciting in cancer treatment because of its potential to enhance the efficacy of immune checkpoint inhibitor-based treatment, improve patient outcomes, and modulate the gut microbiota in beneficial ways,” says Sumanta Pal, MD.
Pembrolizumab/lenvatinib labels updated to include KEYNOTE-B61 data in non-ccRCC
June 28th 2024"The addition of efficacy data from the KEYNOTE-B61 trial reinforces the important role of KEYTRUDA plus LENVIMA as a frontline treatment option for adult patients with advanced RCC regardless of histology," says Takashi Owa, PhD.